(redirected from Tenofovir disoproxil fumarate)
Also found in: Medical.
Related to Tenofovir disoproxil fumarate: emtricitabine


An antiviral drug, C9H14N5O4P, used in the form of a prodrug (tenofovir disoproxil fumarate) to treat chronic hepatitis B and, in combination with other drugs, to treat HIV infection or to reduce the risk of HIV infection.

[teno-, of unknown origin + fo- (alteration of pho(spho)-) + (anti)vir(al).]


n tenofovir m
Mentioned in ?
References in periodicals archive ?
Tenders are invited for Tab Tenofovir Disoproxil Fumarate 300 Mg
The Medicines Patent Pool (MPP) announced an expansion of its current licensing agreement with Gilead Sciences for generic manufacture of tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF) and other Gilead medicines.
The two drug combinations tested include Truvada, which consists of emtricitabine and tenofovir disoproxil fumarate, and Truvada plus maraviroc, which work by blocking the chemokine receptor, CCR5, which is a target entryway of HIV.
Among 4,758 HIV serodiscordant couples in Kenya and Uganda participating in the Partners Pre-exposure Prophylaxis (PrEP) study, the risk of HIV infection was reduced 62% with tenofovir disoproxil fumarate (Viread) (P = .
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
The Public Patent Foundation (New York, NY) said that the United States Patent and Trademark Office has rejected four key HIV/AIDS drug patents held by Gilead Sciences (Foster City, CA) that relate to the drug known generically as tenofovir disoproxil fumarate (TDF), a key weapon in the battle against\ HIV/AIDS.
On May 1, 2001, Gilead Sciences announced the submittal of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of tenofovir disoproxil fumarate (tenofovir DF).
The agreements cover the manufacture of TMC278 as a single agent medicine and a license to develop an FDC product using TMC278 with 300 mg tenofovir disoproxil fumarate and 300 mg lamivudine.
On October 26 the FDA approved Viread (tm) -- generic name tenofovir disoproxil fumarate, or tenofovir DF.
200 mg emtricitabine + tenofovir disoproxil fumarate 245 mg.
World Health Organization guidelines recommend Emtricitabine, as well as Tenofovir Disoproxil Fumarate (TDF), as preferred components of first- and second-line HIV therapy.
Emtricitabine and tenofovir disoproxil fumarate are commercialised by Gilead (NASDAQ:GILD) under the trade names Emtriva(R) and Viread(R), respectively, and are commonly prescribed together as a once-daily, fixed-dose tablet, marketed under the trade name Truvada(R) for use as part of combination therapy.